HOUSTON, June 18, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that the company will be added to the Russell
2000® and 3000® Indexes, effective
after the market close on Friday, June 28,
2019, as part of the Russell Indexes annual
reconstitution.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
FTSE Russell, a British index provider, makes available a
comprehensive range of reliable and accurate indexes used by
investors to measure and analyze global markets across asset
classes, styles or strategies. The Russell U.S. Indexes have
been widely accepted by institutional investors for their academic
integrity and investor usability. Russell U.S. Indexes are part of
FTSE Russell, a leading global index provider. FTSE Russell
determines membership for its Russell U.S. Indexes primarily by
objective, market-capitalization rankings and style attributes.
Membership in the Russell 3000® Index means
automatic inclusion in the large-cap Russell
1000® Index or small-cap Russell
2000® Index, and also includes the appropriate
growth and value style indexes. For more information on the
Russell Indexes go to the "Russell Reconstitution" section on
the FTSE Russell website.
"We are thrilled to be included among the companies that
comprise the Russell Indexes," said Lori
Bisson, Soliton's Chief Financial Officer. "As the FTSE
Russell seeks to benchmark the entire U.S. stockmarket, our
inclusion in these indexes within just five months of our IPO is
gratifying and a validation of the potential we believe investors
see in Soliton's future."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal
methods. Soliton is investigating potential additional
capabilities of the RAP technology in preclinical testing,
including the potential to assist existing fat reduction technology
in the reduction of fat as well as improving the appearance of
cellulite by creating mechanical stress at the cellular level and
inducing significant collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future events,
future expectations, plans and prospects. Although Soliton believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, expectations may prove to have
been materially different from the results expressed or implied by
such forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/soliton-to-be-added-to-the-russell-2000-and-3000-indexes-on-june-28-2019-300870061.html
SOURCE Soliton, Inc.